Bulletin
Investor Alert

New York Markets Close in:

Topics

Johnson & Johnson

/marketstate/country/us

Countdown to close

3:47 p.m.

JNJ
Johnson & Johnson
/zigman2/quotes/201724570/composite

$

165.95

Change

+3.26 +2.00%

Volume

Volume 11.02m

Real time quotes

/zigman2/quotes/201724570/composite

Previous close

$ 162.69

$ 165.95

Change

+3.26 +2.00%

Day low

Day high

$160.85

$167.79

Open

52 week low

52 week high

$133.65

$173.65

Open

Video

WSJ Opinion: Was Pausing Johnson & Johnson's Covid Vaccine a Good Idea?

  • WSJ Opinion: Was Pausing Johnson & Johnson's Covid Vaccine a Good Idea? WSJ Opinion: Was Pausing Johnson & Johnson's Covid Vaccine a Good Idea? 6:04
    Children Under 12 Begin Getting Vaccinated in Pfizer Trials Children Under 12 Begin Getting Vaccinated in Pfizer Trials 1:16
    Fauci Says Children Could Start Getting Vaccinated by Fall Fauci Says Children Could Start Getting Vaccinated by Fall 0:56
    Biden Says Enough Vaccines for All U.S. Adults by End of May Biden Says Enough Vaccines for All U.S. Adults by End of May 1:32
11:46 a.m. Today - Barrons.com
Activists Pressure Corporate Boards to Address Racial Justice, Voting Laws Majority Action and SEIU call on large asset managers to oppose all-white boards and adopt a host of other measures.
11:45 a.m. Today - By Sunny Oh
10-year Treasury yield tumbles below 1.60% as bond bears struggle to gain tractionU.S. Treasury yields fell on Tuesday as losses in global equity markets drew brisk bidding for safe-haven assets like government paper.
11:42 a.m. Today - By Callum Keown
What is the European Super League, and why are soccer fans so upset about it?The proposed European Super League has shaken the foundations of European soccer and sparked almost universal outrage among fans, former players and politicians.
11:24 a.m. Today - By Callum Keown
European Super League backlash grows, as business model for soccer's shakeup becomes clearerThe backlash against European soccer’s proposed Super League grew more vociferous on Tuesday, as more details of the breakaway competition’s business model emerged.
11:18 a.m. Today - By Myra P. Saefong
Oil futures end lower on India's weaker demand prospects, news on anti-OPEC bill Oil futures end lower on Tuesday as record cases of COVID-19 in India dim the outlook for the nation's economy and energy demand, and traders weigh progress on the long-watched NOPEC bill in the U.S.
10:56 a.m. Today - By Andrew Keshner
Johnson & Johnson vaccine 'pause' isn't crimping confidence in the vaccination process, survey saysA CDC advisory committee is scheduled to meet Friday to discuss what’s next for the J&J shot.
10:08 a.m. Today - By William Watts
Dow down for 2nd day as stocks struggle to get lift from earnings beatsU.S. stocks are under pressure for a second day, with investors digesting a deluge of corporate results as earnings reporting season moves into full swing.
10:05 a.m. Today - By Mark DeCambre
Overstock CEO says Coinbase, Robinhood are in its crosshairs as it builds out rival crypto trading venueOverstock CEO Jonathan “JJ” Johnson says he's hoping that one day tZero, a much smaller trading platform that offers some services similar to Coinbase, will be a legitimate rival to the crypto behemoth that just listed on the Nasdaq Inc. last Wednesday with a valuation that briefly hit around $100 billion.
9:31 a.m. Today - By Ciara Linnane
Global tally of COVID-19 cases top 142 million as India's surge raises the alarmThe number of confirmed cases of the coronavirus-borne illness COVID-19 climbed above 142 million on Tuesday, and India remained a hot spot, recording more than 250,000 new infections and over 1,700 deaths in the past 24 hours alone.
9:20 a.m. Today - MarketWatch.com
Ahead of Biden's climate summit, U.K. toughens its greenhouse gas emissions targets Prime Minister Boris Johnson is poised to announce this week stricter greenhouse gas emissions targets for the next 15 years.
9:19 a.m. Today - By Barbara Kollmeyer
Ryan Jacob, the internet fund manager who navigated the dot-com bust, shares two stock tips in the crypto spaceRyan Jacob of the Jacob Internet Fund that got its start in 1999 has been dipping a toe in the hot cryptocurrency space. Here are a pair of stocks he likes.
8:38 a.m. Today - Barrons.com
Stocks Are Lower as Global Covid Cases Hit New Highs The light in Big Tobacco stocks has been put out, following a report that the Biden administration could regulate critical nicotine cutbacks in cigarettes.
8:24 a.m. Today - By Tomi Kilgore
J&J to resume COVID-19 vaccine shipments to EU, with a warning 'very rare' adverse eventsShares of Johnson & Johnson jumped 2.6% toward a 12-week high in midday trading Tuesday, after the drug maker said it will resume shipments of its COVID-19 vaccine in Europe, after should be added. J&J said it will update its COVID-19 vaccine summary of product characteristics to include information on "the diagnosis and management of this very rare adverse event," after which shipment of the vaccine will resume to the European Union, Norway and Iceland. "We appreciate the rigorous review of the PRAC [EMA's Pharmacovigilance Risk Assessment Committee] and share the goal of raising awareness of the signs and symptoms of this very rare event to ensure the correct diagnosis and appropriate treatment," said J&J Chief Scientific Officer Paul Stoffels. "We strongly believe in the positive benefits of our single-shot, easily transportable COVID-19 vaccine to help protect the health of people everywhere and reach communities in need globally." J&J's stock, which is on track for the highest close since Jan. 28, has rallied 10.1% year to date, while the Dow Jones Industrial Average has advanced 10.6%.
J&J to resume vaccine shipments to EU, Norway and Iceland
7:58 a.m. Today
J&J to 'update' vaccine summary to include info on 'very rare' adverse event
7:57 a.m. Today
Johnson & Johnson to resume COVID-19 vaccine roll out in Europe following EMA review
7:56 a.m. Today
7:48 a.m. Today - Barrons.com
Why Is the Stock Market Down Today? Here Are 4 Reasons. Just last Friday, the S&P 500 had closed at a record high. This week, the index can’t seem to find its footing.
7:04 a.m. Today - Barrons.com
European Health Regulators Add Blood Clot Warning to J&J’S Covid-19 Vaccine Overall benefits of the vaccine continued to outweigh the risk of side effects, the European Medicines Agency says.
6:27 a.m. Today - By Steve Goldstein
Johnson & Johnson vaccine should get blood-clot warning, European agency saysThe said its safety committee concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for Johnson & Johnson's coronavirus vaccine, which it said had benefits that outweighed the risk of "very rare" side effects. All eight of the U.S. cases, after more than 7 million vaccinations, occurred in people under 60 years of age within three weeks after vaccination, and mostly in women. The cases reviewed were very similar to the cases that occurred with the COVID-19 vaccine developed by AstraZeneca , the EMA said. The rollout of Johnson & Johnson's vaccine in Europe was paused by the company.
5:31 a.m. Today - By Andrea Riquier
Stocks open lower for a second day despite strong earnings U.S. stocks started Tuesday's session on the back foot after retreating from fresh records Monday, even as quarterly corporate results continued to come in strong. The Dow Jones Industrial Average dipped 120 points, 0.4%, to open near 33,597, while the S&P 500 lost 11 points, 0.3%, and started trading near 4,153. The Nasdaq Composite shed 11 points,0.1%, and traded near 13,904. Stock-market bellwethers like International Business Machines Corp. and Johnson & Johnson both beat analyst expectations. IBM shares were nearly 3% higher after the bell, while Johnson & Johnson share dipped.
4:26 a.m. Today - Barrons.com
Johnson & Johnson Just Reported Earnings. This Number Is Critical. First-quarter sales of medical devices, which plunged in 2020 as a result of the pandemic, came in higher than in the first three months of 2019.
4:16 a.m. Today - Barrons.com
What Doge Day Means for Crypto Facebook enters the social audio space, Apple is likely to launch new iPads today, Biden continues to lobby for infrastructure package, and other news to start your day.
4:12 a.m. Today - MarketWatch.com
Plans for NFL-style European soccer Super League create uproar French President Emmanuel Macron as well as U.K. Prime Minister Boris Johnson joined the furor on Monday to say they would support efforts to scuttle the attempt to create the Super League.
2:45 a.m. Today - By Tomi Kilgore
J&J beats profit and sales expectations, boosts dividend; COVID-19 vaccine adds $100 million to salesJohnson & Johnson reported Tuesday first-quarter profit and sales that rose above expectations, citing strength in its pharmaceutical business and continued recovery in medical devices. The drug giant's stock slipped 0.2% in premarket trading. Net income increased to $6.20 billion, or $2.32 a share, from $5.80 billion, or $2.17 a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share grew 12.6% to $2.59, above the FactSet consensus of $2.34. Sales increased 7.9% to $22.32 billion, beating the FactSet consensus of $21.98 billion. Pharmaceutical sales rose 9.6% to $12.20 billion, to top the FactSet consensus of $12.11 billion, while medical devices sales increased 10.9% to $6.58 billion to beat expectations of $6.21 billion. COVID-19 vaccine sales were $100 million. For 2021, the company revised its adjusted EPS guidance range to $9.42 to $9.57 from $9.40 to $9.60. Separately, J&J said it raised its quarterly dividend by 5% to $1.01 a share, with the new dividend payable June 8 to shareholders of record on May 25. The stock has gained 3.4% year to date through Monday, while the Dow Jones Industrial Average has advanced 11.3%.
J&J raises quarterly dividend by 5% to $1.06 a share
2:34 a.m. Today
J&J revises 2021 adj. EPS outlook to $9.42-$9.57 from $9.40-$9.60
2:34 a.m. Today
J&J Q1 pharmaceutical sales $12.20 bln vs. $11.13 bln; FactSet consensus $12.11 bln
2:33 a.m. Today
Johnson & Johnson Q1 sales $22.32 bln vs. $20.69 bln a year ago; FactSet consensus $21.98 bln
2:32 a.m. Today
Johnson & Johnson Q1 adj. EPS $2.59 vs. $2.30 a year ago; FactSet consensus $2.34
2:31 a.m. Today
Johnson & Johnson Q1 EPS $2.32 vs. $2.17 a year ago
2:31 a.m. Today
10:54 p.m. April 19, 2021 - MarketWatch.com
India's capital imposes fresh lockdown as health system buckles under soaring COVID-19 cases Just months after India thought it had seen the worst of the pandemic, the virus is now spreading at a rate faster than at any other time, said Bhramar Mukherjee, a biostatistician at the University of Michigan who has been tracking infections in India.
9:38 p.m. April 19, 2021 - MarketWatch.com
Japan stocks tumble 2% in mixed day for Asian markets after Wall Street's slideTraders are uneasy about a rise in inflation and interest rates and renewed coronavirus infections that prompted some governments to reimpose anti-disease controls.
1:32 p.m. April 19, 2021 - By MarketWatch Automation
1:29 p.m. April 19, 2021 - By MarketWatch Automation
1:26 p.m. April 19, 2021 - By MarketWatch Automation
1:26 p.m. April 19, 2021 - By MarketWatch Automation
1:25 p.m. April 19, 2021 - By MarketWatch Automation
1:19 p.m. April 19, 2021 - By MarketWatch Automation
1:16 p.m. April 19, 2021 - By MarketWatch Automation
1:16 p.m. April 19, 2021 - By MarketWatch Automation
Browse topics:

Filter results by

Location

Us (720)

Europe (323)

Eu (249)

Asia Pacific (232)

China (215)

Japan (180)

Issue

General (396)

Markets/exchanges (299)

Economy (232)

Market News (227)

Opinion (225)

Commodities (221)

Link to MarketWatch's Slice.